rotigotine

(redirected from Neupro)

rotigotine

an antiparkinson agent.
indication This drug is used to treat idiopathic Parkinson's disease.
contraindications Defibrillation, MRI, and known hypersensitivity to this drug prohibit its use.
adverse effects Adverse effects of this drug include drowsiness, hallucinations, headache, malaise, paresthesia, vertigo, confusion, dizziness, dyskinesia, fatigue, fever, insomnia, sudden sleep onset, edema, hypertension, sinus tachycardia, orthostatic hypotension, dyspepsia, anorexia, constipation, vomiting, xerostomia, weight gain, urinary incontinence, dermatitis, erythema, rash, pruritus, purpura, arthralgia, and back pain. A life-threatening side effect is anaphylaxis. A common side effect is nausea.
References in periodicals archive ?
Cimzia, Vimpat and Neupro generated combined net sales of EUR 433 million, while anti-epilepticA drugA Keppra reached EUR 190 million.
NEUPRO is indicated for the treatment of Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS).
Neupro (rotigotine) is a dopamine agonist available as a patch that has been approved for the treatment of RLS as well as Parkinson disease.
Our study shows you individual revenue forecasts to 2024 for three leading products: -- Comtan and Stalevo -- Azilect -- Neupro.
Neupro Patch is the only transdermal dopamine agonist system available in the world, which only needs to be applied once a day, enabling a clinically-effective blood drug concentration via stable drug delivery throughout a 24-hour period.
NEW ORLEANS--A reformulated version of the previously withdrawn Neupro rotigotine patch had favorable results in separate studies of patients with advanced idiopathic Parkinson's disease and restless legs syndrome, according to reports given before the planned return of the patch to the U.
The growth was mainly due to rising revenue from the new products Cimzia, Vimpat and Neupro which made combined sales of EUR 134 million, up by 76% year-on-year.
the manufacturer of Neupro (rotigotine transdermal system), recalled the drug as a deviation from approved product standards was noted that reduced treatment effectiveness.
UCB shares have declined 15% this year after the company recalled batches of its Neupro patch for Parkinson's disease and encountered generic competition for Zyrtec.
Company Product Name Approval Date Function Schwarz Neupro May 9, 2007 Neupro is the first Bioscience (rotigotine transdermal patch transdermal approved for the system) treatment of symptoms of Parkinson's disease.
may be directly interpreted as a neural net and as a NeuPro code.
34 billion, thanks to increased sales of the group's core medicinesA Cimzia, Vimpat and Neupro.